Similar Search Results

Adverse effects of patent pooling on product development and commercialization

Jeitschko, Thomas D.; Zhang, Nanyun - In: The B.E. journal of theoretical economics 14 (2014) 1, pp. 27-57

Persistent link: https://www.econbiz.de/10010417576

Neglected dimension of the inventive step as applied to pharmaceutical and biotechnological products : the case of Sri Lanka's patent law

Fernando, Ruwan - 2023

-Related Aspects of Intellectual Property Rights (TRIPS) and its biotechnology/pharmaceutical policy guidelines. This approach that is …

Persistent link: https://www.econbiz.de/10014324836

The US Patent Holdings of Homegrown Indian Biotech and Pharma Companies

Sundaramoorthy, Sriramkumar; Yerram, Chandra Bindu; … - 2016

We have examined all the US patents (444) issued to homegrown Indian pharma and pharma biotech firms. Most (425, 95%) patents are pharma patents not biotech (19). Also, only 11 patents have been cited ten times or more. This data provides one snapshot of the biotech industry in India today. It...

Persistent link: https://www.econbiz.de/10014129813

Creating knowledge assets under biocapitalism : analyzing China's biomedical industry and its patent networks

Zhou, Yu; Sun, Feixiang - In: Economic geography 98 (2022) 5, pp. 411-437

Persistent link: https://www.econbiz.de/10013484806

What about Know-How : Heightened Obviousness and Lowered Disclosure is Not a Panacea to the American Patent System for Biotechnology Medication and Pharmaceutical Inventions in the...

Su, Yi-Chen - 2013

In KSR International, the U.S. Supreme Court rejected the Federal Circuit's rigid application of “teaching, suggestion, or motivation” test (TSM test), and replaced it with an “expansive and flexible” approach, in determining the question of obviousness. Nevertheless, an expansive and...

Persistent link: https://www.econbiz.de/10013095605

Shaping the industrial century : the remarkable story of the evolution of the modern chemical and pharmaceutical industries

Chandler, Alfred Dupont - 2005

Persistent link: https://www.econbiz.de/10002225935

Transferts de technologie et politique de l'innovation : le cas des biotechnologies

Sharp, Margaret - In: Les défis de la mondialisation : innovation et concurrence, (pp. 155-212). 1994

Persistent link: https://www.econbiz.de/10001289408

Is Europe a Laggard in Pharmaceuticals? R&D Joint Ventures, Patent Quality and R&D Productivity

Messinis, George - 2009

This paper examines the idea that the USA has outshined Europe in the race for new medicines as a result of a flight of … study provides three new insights: (a) R&D expenditure yields more patents in the USA but this is due to Europe's superior …

Persistent link: https://www.econbiz.de/10013155663

Firm level R&D intensity : evidence from Indian drugs and pharmaceutical industry

Tyagi, Shilpi; Nauriyal, D. K.; Gulati, Rachita - In: Review of managerial science 12 (2018) 1, pp. 167-202

Persistent link: https://www.econbiz.de/10011824348

Crisis and change in the system of innovation : the Japanese pharmaceutical industry during the Lost Decades, 1990 - 2010

Umemura, Maki - In: Business history 56 (2014) 5, pp. 816-844

Persistent link: https://www.econbiz.de/10010429323

1
2
3
4
5
6
7
8
9
10
Next
Last